Resources
20 Results (showing 1 - 10)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 5/3/2021 (updated 4/10/2024)
The U.S. Food and Drug Administration (FDA) announced on April 30, 2021 the approval of a higher dose naloxone hydrochloride nasal spray product to treat opioid overdose. The newly approved product delivers 8 milligrams (mg) of naloxone into the nasal cavity. The FDA had previously approved 2 mg and 4 mg naloxone nasal spray products.
Naloxone is a medicine that can be administered by individuals with or without medical training to help reduce opioid overdose deaths. If naloxone is administered quickly, it can counter the opioid overdose effects, usually within minutes. A higher dose of naloxone provides an additional option in the treatment of opioid overdoses.
Posted 10/14/2021 (updated 4/3/2024)
Stimulant intoxication, withdrawal, and psychosis have accepted and established treatment strategies. Several lifesaving harm reduction interventions/services are available. There are no Food and Drug Administration-approved medications for treatment of stimulant use disorder, although several are promising. Behavioral treatment, especially the use of contingency management (and other approaches with supportive evidence), has by far the best evidence of effectiveness. The presenter reviewed topics of importance to clinicians treating individuals with stimulant use disorder.
Rick Rawson, PhD, University of Vermont Rural Center of Excellence
Posted 9/30/2020 (updated 3/29/2024)
This packet presents Implementation II grantees with tools and strategies to support implementation activities that expand the options for SUD/OUD services across the care spectrum, thereby helping rural residents in your community to prevent SUD/OUD, access treatment, and move toward recovery.
Posted 9/18/2020 (updated 3/29/2024)
This is the template for the PIII Community Needs Assessment and Gap Analysis deliverable.
Posted 9/18/2020 (updated 3/29/2024)
We have included information that will be relevant
to the broad range of HRSA RCORP-Planning grantees.
We encourage you to work through this packet section by
section, keeping in mind the timeline for final submission of
core grant deliverables.
Posted 9/14/2020 (updated 3/29/2024)
The RCORP-TA Policy Academy Town Hall took place on September 1, 2020.
Please find the presentation and recording posted here.
Posted 9/4/2020 (updated 3/29/2024)
The RCORP-TA Policy Academy and Learning Collaborative Orientation Webinar took place on August 25, 2020. Please find the presentation and recording posted here.
Posted 12/31/2019 (updated 3/28/2024)
A Draft Working Document for the American Samoa Department of Human and Social Services’ Strategic Planning Initiative May 8-10, 2018. Adapted by JBS International for SAMHSA’ s State TA Project.
Posted 12/30/2019 (updated 3/28/2024)
Pharmacotherapy of Opioid Use Disorder Webinar Presentation and Resources
Posted 11/19/2019 (updated 3/28/2024)
This guidance document is intended to support the development of comprehensive prevention. Work Plans that are based on local data and designed to achieve measurable outcomes.